Cameron S. Carter, M.D.
Journal Articles
2015
McFarlane WR, Levin B, Travis L, Lucas FL, Lynch S, Verdi M, Williams D, Adelsheim S,
Calkins R, Carter CS, Cornblatt B, Taylor SF, Author AM, McFarland B, Melton R,
Migliorati M, Niendam T, Ragland JD, Salo T, Salvador M, Spring L. Clinical and
functional outcomes after two years in the Early Detection and Intervention for the
Prevention of Psychosis multisite effectiveness trial. Schizophrenia Bulletin 41(1): 30-43.
2015
Solomon M, Frank MJ, Ragland JD, Smith AC, Niendam TA, Lesh TA, Grayson DS,
Beck JS, Matter JC, Carter CS. Feedback-driven trial-by-trial learning in autism
spectrum disorders. American Journal of Psychiatry 172 (2): 173-81.
2015
Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JHY, Minzenberg MJ, Ragland JD,
Solomon M, Carter CS. A multimodal analysis of antipsychotic effects on brain structure
and function in first-episode schizophrenia. Jama Psychiatry 72 (3): 226-34.
2015
Poppe AB, Carter CS, Minzenberg MJ, MacDonald AW 3rd. Task-based functional
connectivity as an indicator of genetic liability. Schizophrenia Research 162(1-3): 11823.
2015
Kappenman ES, Luck SJ, Kring AM, Lesh TA, Mangun GR, Niendam TA, Ragland JD,
Ranganath C, Solomon M, Swabb TY, Carter CS. Electrophysiological evidence for
impaired control of motor output in schizophrenia. Cerebral Cortex.
2015
Jarskog LF, Lowy MT, Grove RA, Keefe RSE, Horrigan JP, Ball MP, Breier A, Buchanan
RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS,
Laurell M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian
MA. A phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive
impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia
Research 164 (1-3): 136-42.
2015
Sheffield JM, Repovs G, Harms MP, Carter CS, Gold JM, MacDonald AW 3rd, Ragland
JD, Silverstein SM, Godwin D, Barch DM. Fronto-parietal and cingulo-opercular network
integrity and cognition in health and schizophrenia. Neuropsychologia 73: 82-93.
Presentations
2014 University of Newcastle, Australia “Attention Lapses and Cognitive Control in
Schizophrenia,” July 14.
2014 ICON International Conference Brisbane, Australia “CNTRICS and Beyond,” July 27.
2014 International Society for CNS Clinical Trials Methodology Boston, MA “Basic Science for
Clinical Trials: CNTRICS and CNTRACS Update,” October 6.
20
2014 Molecular Psychiatry Association Meeting San Francisco, CA “Cognition Impairment in
Schizophrenia: Underlying Mechanisms,” November 7.
2015 Congress Capitol Hill, Washington, DC “Mental Health Research at UC Davis,” January
28.
2015 Psychiatric Research Society Annual Meeting, Park City, UT “Prefrontal Mechanisms of
Impaired Cognition in Schizophrenia,” February 3.
2015 Mission Bay Conference San Francisco, CA “Prevention and Intervention at UC Davis,”
April 3.
2015 UC Davis-FAPESP Workshop, Sao Paulo, Brazil “Integrative Neuroscience at UC Davis,”
May 11.
2015 University of Queensland, Brisbane, Australia “Integrative Neuroscience for Mental
Health,” June 14.
2015 Computational Psychiatry Forum, Frankfurt, Germany “Cognitive Control in
Schizophrenia,” June 27.
Research Funding
MH059883, (Carter C: PI) 3/15/00-3/31/18, “Pathophysiology of Cognitive Disability in
Schizophrenia,” $523,988.
2 T32MH082174-06A1 (Carter C: PI) 8/01/07-6/30/19 “Training Program in Basic
Neuroscience,” $168,154.
MH084826 NCI. (Carter C: PI) 9/30/08-6/30/17, “2/5-Cognitive Neuroscience Task Reliability &
Clinical Applications Consortium,” $262,173.
HHSN-DA-12-242, (Carter C: Co-PI; Subcontract for Carter C) 8/29/13-10/28/15 “New
Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum Disorders (FAST-PS)”
$499,061.
1 R01MH104235-01, (Carter C: PI) 9/01/14-7/31/18 “Reducing Duration of Untreated Psychosis
Through Rapid Identification and Engagement,” $856,584.
1 P50MH106438-01, (Carter C: PI) 4/01/15-3/31/20 “UC Davis Conte Center Neuroimmune
Mechanisms of Psychiatric Disorders,” $2,000,000.
SacEDAPT Prevention and Early Intervention Contract, Sacramento County $640,000.
Community Service
Academic Adviser, Graduate Group in Clinical Research
Associate Editor, American Journal of Psychiatry
21
Chair, Search Committee, Center for Neuroscience/Psychiatry Department
Chair, Search Committee, Physiology and Membrane Biology, School of Medicine, UC Davis
Deputy Editor, Biological Psychiatry
Director, Schizophrenia Research and Education Program
Director, UC Davis Behavioral Health Center for Excellence
Director, UC Davis Conte Center
Director, UC Davis Imaging Research Center
Director, Center for Neuroscience
Director, Early Diagnosis and Preventative Treatment (EDAPT) Clinic
Member, ACNP Honorific Awards Committee
Member, Alzheimer’s Disease Center Advisory Committee, Department of Neurology
Member, Basic Science Council
Member, Editorial Board, Psychiatry Research: Neuroimaging
Member, Editorial Board, Neuropscyhopharmacology
Member, Internal Advisory Committee, BIRCH Scholars Program
Member, Internal Advisory Committee, UC Davis Center for Mind and Brain
Member, Melbourne Neuropsychiatry Centre Scientific Advisory Committee
Member, Mentoring Academy Steering Committee
Member, Scientific Council, National Alliance for Research on Schizophrenia and Depression
(NARSAD)
Member, UC Davis Campus Advisory Committee for the MIND Institute
Member, UCLA Center for Neurocognition and Emotion in Schizophrenia External Research
Advisory Panel
22